What We Can Learn from Underperforming Clinical Trial Sites

Introduction: Why Underperformance Deserves Serious Review

While much attention is given to high-performing clinical trial sites, underperforming sites hold equally valuable insights. Whether it’s delays in startup, failure to enroll, data quality issues, or protocol non-compliance, these sites represent high-risk nodes that impact trial timelines, regulatory confidence, and overall study cost. Reviewing lessons from past site underperformance is critical for enhancing feasibility planning, refining site selection SOPs, and building future-ready oversight systems.

In this article, we examine key patterns of site underperformance, common root causes, and how sponsors and CROs can integrate these findings into performance scoring systems and qualification frameworks.

1. Defining Underperformance in Clinical Trial Sites

Underperformance refers to a site’s inability to meet one or more of the following performance expectations:

• Timely site activation and study startup
• Subject enrollment goals within protocol-defined timeframes
• Compliance with GCP and protocol procedures
• Reliable and timely data entry and query resolution
• Retention of subjects through trial completion
• Readiness and cooperation during audits and inspections

A site failing in any of these dimensions may generate delays, require excessive oversight, or pose inspection risks—ultimately undermining trial quality.

2. Common Characteristics of Underperforming Sites

Data across studies reveal that poor-performing sites often share a set of recurring features:

• Delayed IRB submission or contract finalization
• Frequent staffing changes, especially untrained coordinators
• Lack of PI engagement in subject recruitment and monitoring
• High screen failure rates without justification
• Protocol deviations from dosing, visit windows, or assessments
• Low or stagnant enrollment after SIV
• Multiple unresolved queries at database lock
• Negative CRA feedback across multiple monitoring visits

Sites with three or more of these attributes in prior studies are often placed on performance watchlists or excluded from future site rosters.

3. Root Causes Behind Poor Site Performance

Sponsors and CROs often conduct root cause analyses (RCA) post-study to identify why a site underperformed. Common causes include:

• Over-commitment: Site accepted multiple concurrent studies beyond capacity
• Weak prescreening processes: High screen failure rates
• Lack of training: Protocol misunderstood by sub-investigators
• Infrastructure gaps: Missing equipment or storage issues
• Miscommunication: CRA and site coordinators not aligned
• Unrealistic feasibility submissions: Inflated subject availability claims

Identifying and documenting these root causes is essential for requalification decisions and future feasibility questionnaires.

4. Case Study: Site Startup Failure

In a global infectious disease study, Site 021 was selected based on a compelling feasibility response and previous participation in a similar Phase II trial. However:

• IRB approval took 76 days due to staff turnover
• SIV was delayed by 38 days due to contract amendments
• No subjects were enrolled after three months of activation
• CRA feedback flagged lack of engagement by the PI

Post-study RCA revealed the site had ongoing renovations that were not disclosed during the feasibility process. The site was removed from the active site list for subsequent protocols in the region.

5. Enrollment Metrics of Underperforming Sites

Enrollment data is a clear performance indicator. Sites performing below expected recruitment rates contribute to costly timeline extensions and amendments. Consider the table below:

Site C enrolled zero subjects due to internal prioritization of another trial and was closed before midpoint. Benchmarking these data points supports proactive feasibility filtering.

6. Regulatory Risks and Audit Flags from Low-Performing Sites

Underperforming sites are more likely to be cited during audits and inspections. Findings may include:

• Incomplete informed consent forms
• Improper temperature monitoring for IP
• Backdated source documents
• Untrained staff conducting assessments

Regulators such as the FDA and EMA expect sponsors to monitor site performance and take corrective actions. Failure to exclude or retrain poor sites may expose the sponsor to inspection findings.

7. Integrating Underperformance Lessons into Feasibility Models

Sponsors and CROs can build learnings from underperformance into feasibility and selection SOPs:

• Require documented PI involvement in prior studies
• Track screen failure and dropout rates over time
• Use performance dashboards with risk scores
• Flag unrealistic feasibility questionnaire responses
• Conduct pre-qualification site audits where prior risk exists

Tip: Create a “Do Not Engage” list for sites that have failed in two or more studies within a 3-year window—backed by objective performance data.

8. Using CTMS and Dashboards to Monitor for Decline

Tools such as Clinical Trial Management Systems (CTMS) and risk-based monitoring dashboards can flag performance deterioration in real time. Common alerts include:

• Enrollment drop-off
• Escalating deviation trends
• Delayed data entry or unresolved queries
• Staff turnover flags in CRA visit notes

Such systems allow proactive interventions or withdrawal decisions before site issues affect study timelines.

Conclusion

Underperforming clinical trial sites not only disrupt timelines and budgets—they compromise data quality and expose sponsors to regulatory scrutiny. By systematically capturing and analyzing the patterns and causes of site underperformance, sponsors and CROs can improve feasibility processes, strengthen qualification SOPs, and focus trial activities on the most capable, committed, and compliant partners. Lessons from failure are not setbacks—they are critical steps toward future trial success.